BioAtla presented poster of Phase 2 trial data at ESMO meeting

BioAtla presented a poster of Phase 2 trial data at the European Society for Medical Oncology, ESMO, Annual Meeting. The poster presentation entitled, “Phase 2 trial of ozuriftamab vedotin, a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck,” reported multiple confirmed responses among heavily pretreated patients who tolerated treatment well. The Company’s novel, conditionally active anti-ROR2-ADC was recently granted FDA Fast Track Designation for treatment of patients with recurrent or metastatic SCCHN. Among 31 evaluable patients: Ten responses overall: ORR 32% across both dosing regimens; Responses and SD were observed regardless of HPV status and ROR2 expression; Overall DCR across both dosing regimens was 77%; Responses were confirmed among 6 responding patients; Median duration of response for all confirmed responders is not yet reached. Treatment with ozuriftamab vedotin was well tolerated